Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (420)	1/6/2000 12:22:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 1834

Richard, Thanks for the perspective. Don't get me wrong, I'm not really complaining. I'm accumulating this one in fairly decent sized chunks and I'll probably keep doing so. I looked through their pipeline and I like it. I like the insomnia program. I've used Ambien for years and I know the effects of it. If they have one that is as effective but without the side effects of Ambien, it'll do well. Ambien is an excellent drug, but it tends to stay in your system for part of the following day and it also has some severe rebound problems that become even more pronounced even with long term occasional use. Fortunately for me, I really don't own any of the stocks that appreciated massively in 1999. Although I know more than most about the Internet, I never bought a single share of an Internet company. I suppose I could have made lots of money on it, but I just can't get myself to buy stock that needs to be discounted to Y3K before it the fundamentals make sense. As an aside, I saw the Amazon.Com story and I'm really amazed at the idiocy involved. They had a good chance at becoming an excellent book seller and that could be done with very limited inventories. But then they had to go and mess with toys, music and electronics. In all cases, they went up against so many others in the market. The margins aren't that great and you do need to carry inventory. And now they're having to write a lot of that down. Thanks again for the perspective. Regards, Torben

To: scaram(o)uche who wrote (420)	1/6/2000 9:34:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

<<There may be some negative sentiment toward the Taisho deal from those who actually do know the company and its programs. They may fear that NBIX is committing to 50% of development costs for a program that isn't in the "top three" (insomnia, depression/anxiety, IL4 fusion toxin).>> I am one who have mixed filling about this deal. I am glad that they did partner program, but I do not like idea that they pay 50% for EU and Japan clinical trials, if this is a case and/or royalty are <50% . <<This (Taisho) is a very good deal in a program which I valued at $0. They could do a similar deal for the U.S. and walk with milestones and royalties for free. If they like their chances, they won't do such. In that event, our leverage just became even more pronounced. Either way, shareholders win.>> I would like to see some more visible value from their neuro-immuno-inflammatory programs (MS, Diabetes, chemokine antagonists,...). Their expense and efforts so far are significant and I do hope that it isn't waste of finance and man-power source. I didn't give-up completely on APL for MS, and this Taisho deal indicate that initial NBI-6024 PI trial went OK. Going further with NBI-6024 will require significant $$$$ (long trials). If drug is dumb better stop now and continue with neuro programs more aggressively. NBIX seems confident in drug, so I do hope that there is more value than we are willing to assignee. Miljenko